TrialHaematologica2009

High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.

François Guilhot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.